RCT | Trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial – The Lancet